Blockbuster drug Humira finally faces lower-cost rivals
After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.
Source: wsiu.org
Page 6 - Program On Regulation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Program On Regulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Program On Regulation Today - Breaking & Trending Today
Yusimry's bargain price could give it an edge over Humira : Shots
After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.
Source: npr.org
Blockbuster drug Humira finally faces lower-cost rivals
After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.
Source: wpsu.org
Opinion | FDA should limit approval of new Alzheimer's drug Leqembi
All medicines with marginal effectiveness and worrisome side effects should be used sparingly until better evidence is collected.
Source: washingtonpost.com
Do Orphan Drugs Really Need Development Incentives?
Study finds no difference in revenue between drugs for rare diseases and the general population
Source: medpagetoday.com